✦ LIBER ✦

Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer

✍ Scribed by Lee F. Allen; Peter F. Lenehan; Irene A. Eiseman; William L. Elliott; David W. Fry

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

CI-1033, an irreversible pan-erbB recept

✍ Lee F Allen; Irene A Eiseman; David W Fry; Peter F Lenehan 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 474 KB

A randomized, phase II, dose-finding stu

✍ Olivier Rixe; Sandra X. Franco; Denise A. Yardley; Stephen R. Johnston; Miguel M 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 367 KB

HER (erbB) tyrosine kinase inhibitors in

✍ Carlos L. Arteaga; Stacy L. Moulder; F.Michael Yakes 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 153 KB

The potential role of the EGFR/ERBB2 het

✍ Cicenas, Jonas 📂 Article 📅 2007 🏛 Informa plc 🌐 English ⚖ 295 KB

Lapatinib, a Dual ErbB-1/ErbB-2 Kinase I

✍ Susan R. Peck; Joyce A. O'Shaughnessy 📂 Article 📅 2006 🏛 CIG Media Group, LP. 🌐 English ⚖ 95 KB

Aromatase Inhibitors in the Treatment of

✍ Brueggemeier, Robert W.; Hackett, John C.; Diaz-Cruz, Edgar S. 📂 Article 📅 2005 🏛 Endocrine Society 🌐 English ⚖ 558 KB